{"filing":{"accession_number":"0001140361-26-035859","cik":"0001635088","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ef20081686_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_8k.htm"},"events":[{"id":31875,"run_id":29274,"accession_number":"0001140361-26-035859","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces positive Phase 2 clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, including achievement of primary and secondary endpoints with statistically significant improvements in pulmonary vascular resistance (-56.3%), six-minute walk distance (+35.2m), and NT-proBNP reduction (-53.2%). The filing also announces initiation of a Phase 3 trial (PHrontier). This is a material clinical development milestone for a biopharmaceutical company's pipeline asset, representing significant progress toward potential regulatory approval and commercialization, though it does not fit neatly into the specific financial, governance, or legal event categories.","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34903,"accession_number":"0001140361-26-035859","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, including achievement of primary and secondary endpoints with statistically significant improvements in pulmonary vascular resistance (-56.3%), six-minute walk distance (+35.2m), and NT-proBNP reduction (-53.2%). The filing also announces initiation of a Phase 3 trial (PHrontier). This is a material clinical development milestone for a biopharmaceutical company's pipeline asset, representing significant progress toward potential regulatory approval and commercialization, though it does not fit neatly into the specific financial, governance, or legal event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:16:41.837107+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34903,"accession_number":"0001140361-26-035859","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, including achievement of primary and secondary endpoints with statistically significant improvements in pulmonary vascular resistance (-56.3%), six-minute walk distance (+35.2m), and NT-proBNP reduction (-53.2%). The filing also announces initiation of a Phase 3 trial (PHrontier). This is a material clinical development milestone for a biopharmaceutical company's pipeline asset, representing significant progress toward potential regulatory approval and commercialization, though it does not fit neatly into the specific financial, governance, or legal event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:16:41.837107+00:00","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-09-08"}]}